Safety, tolerability, and clinical activity of selinexor in combination with pembrolizumab in treatment of metastatic non-small cell lung cancer.
Mehmet AltanJanet TuDenái R MiltonBulent YilmazYanyan TianFrank V FossellaFrank E MottGeorge R BlumenscheinBettzy StephenDaniel D KarpFunda Meric-BernstamJohn V HeymachAung NaingPublished in: Cancer (2023)
New strategies to prevent or reverse resistance to immune checkpoint inhibitors are under investigation. Selective inhibitors of nuclear export proteins, such as selinexor, can induce restoration of tumor-suppressing pathways and induce potent immunomodulatory activities. This article contains the clinical safety and early efficacy data on the combination of pembrolizumab and selinexor in treatment of metastatic non-small cell lung cancer.